Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) and Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Decoy Therapeutics and Nabriva Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Nabriva Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 275.47%. Given Decoy Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Nabriva Therapeutics.
Risk & Volatility
Institutional & Insider Ownership
11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Decoy Therapeutics and Nabriva Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Decoy Therapeutics | N/A | N/A | -$5.58 million | ($406.89) | -0.02 |
| Nabriva Therapeutics | $35.59 million | 0.00 | -$57.19 million | ($19.20) | 0.00 |
Decoy Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Decoy Therapeutics and Nabriva Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Decoy Therapeutics | N/A | -401.05% | -155.77% |
| Nabriva Therapeutics | -148.11% | -365.53% | -135.81% |
Summary
Nabriva Therapeutics beats Decoy Therapeutics on 7 of the 13 factors compared between the two stocks.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
